Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches

Reid, AT; Veerati, PC; Gosens, R; Bartlett, NW; Wark, PA; Grainge, CL; Stick, SM; Kicic, A; Moheimani, F; Hansbro, PM; Knight, DA

Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches

Reid, AT Veerati, PC Gosens, R Bartlett, NW Wark, PA Grainge, CL Stick, SM Kicic, A Moheimani, F Hansbro, PM

Knight, DA

Permalink

Publication Type:: Journal Article
Citation:: Pharmacology and Therapeutics, 2018, 185 pp. 155 - 169
Issue Date:: 2018-05-01

Closed Access

	Filename	Description	Size
	1-s2.0-S0163725817303066-main.pdf	Published Version	1.2 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Reid, AT	en_US
dc.contributor.author	Veerati, PC	en_US
dc.contributor.author	Gosens, R	en_US
dc.contributor.author	Bartlett, NW	en_US
dc.contributor.author	Wark, PA	en_US
dc.contributor.author	Grainge, CL	en_US
dc.contributor.author	Stick, SM	en_US
dc.contributor.author	Kicic, A	en_US
dc.contributor.author	Moheimani, F	en_US
dc.contributor.author	Hansbro, PM https://orcid.org/0000-0002-4741-3035	en_US
dc.contributor.author	Knight, DA	en_US
dc.date.issued	2018-05-01	en_US
dc.identifier.citation	Pharmacology and Therapeutics, 2018, 185 pp. 155 - 169	en_US
dc.identifier.issn	0163-7258	en_US
dc.identifier.uri	http://hdl.handle.net/10453/128330
dc.description.abstract	© 2017 Dysregulated induction of goblet cell differentiation results in excessive production and retention of mucus and is a common feature of several chronic airways diseases. To date, therapeutic strategies to reduce mucus accumulation have focused primarily on altering the properties of the mucus itself, or have aimed to limit the production of mucus-stimulating cytokines. Here we review the current knowledge of key molecular pathways that are dysregulated during persistent goblet cell differentiation and highlights both pre-existing and novel therapeutic strategies to combat this pathology.	en_US
dc.relation.ispartof	Pharmacology and Therapeutics	en_US
dc.relation.isbasedon	10.1016/j.pharmthera.2017.12.009	en_US
dc.subject.classification	Pharmacology & Pharmacy	en_US
dc.subject.mesh	Goblet Cells	en_US
dc.subject.mesh	Animals	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Respiratory Tract Diseases	en_US
dc.subject.mesh	Signal Transduction	en_US
dc.subject.mesh	Cell Differentiation	en_US
dc.title	Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches	en_US
dc.type	Journal Article
utslib.citation.volume	185	en_US
utslib.for	1115 Pharmacology and Pharmaceutical Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	closed_access
pubs.publication-status	Published	en_US
pubs.volume	185	en_US

Abstract:

© 2017 Dysregulated induction of goblet cell differentiation results in excessive production and retention of mucus and is a common feature of several chronic airways diseases. To date, therapeutic strategies to reduce mucus accumulation have focused primarily on altering the properties of the mucus itself, or have aimed to limit the production of mucus-stimulating cytokines. Here we review the current knowledge of key molecular pathways that are dysregulated during persistent goblet cell differentiation and highlights both pre-existing and novel therapeutic strategies to combat this pathology.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/128330